Neutralize Covid-19 Impact on Drug Prices And Market Access For Faster Recovery

Covid-19 pandemic that has not spared any facet of human lives and livelihoods, has also reignited several ongoing debates related to the drug industry. The need to urgently resolve these issues grows manifold, as the real magnitude of this health … Continue reading

What Pays More: Creating ‘Innovative ‘Customer Experience’ Or ‘Innovative Drugs’?

More innovative a drug is, the better is its business success rate. This was the general perception of around 92 percent pharma professionals in the past three years. Whereas the fact is: ‘Having the best product doesn’t guarantee sales anymore’. … Continue reading

Continues ‘The Cat And Mouse Game’ In Pharma Business?

Many are already aware of the critical factors that make generic drugs so important for patients – virtually for all. These don’t just facilitate greater access to health care – offering affordable alternatives to high-priced off-patent innovative drugs. This is … Continue reading

Gene Therapy Price: Commercial Viability And Moral Dilemma

On May 24, 2019, Novartis announced the US-FDA approval of ‘the first and only gene therapy’ – Zolgensma, for a type of Spinal Muscular Atrophy (SMA), a lifesaving treatment for infants of less than 2 years of age. This unique drug halts disease progression … Continue reading

Focus On Patient Compliance To Boost Pharma Sales…And More…

One high-impact area in the healthcare space that often finds its place in the backseat is – patient noncompliance. A term that is commonly used in regard to ‘a patient who does not take a prescribed medication or follow a prescribed course … Continue reading

Pharma’s Oncology Focus: Some Key Drivers With Pros And Cons For Patients

Just in the first ten days of the brand-new year – 2019, three important oncology focused acquisitions were announced by three top global pharma companies. On January 03, 2019, Bristol-Myers Squibb announced that it will acquire Celgene for a hefty sum of USD … Continue reading

Protect Generic Drug Margin Moving Up The Value Chain

As an innovative drug molecule goes off-patent, it paves the way for market-entry of cheaper generic equivalents of the same. It benefits not just the patients, but all generic drug players awaiting this opportunity. But, in case of even those … Continue reading

An Interesting demand: No Price Control For OTC Drugs

Since over a decade, some pharma trade organizations operating in India, have been advocating for a separate regulatory policy for ‘Over The Counter (OTC)’ drugs, which can be legally sold without any medical prescriptions. Such a new policy initiative, if taken by … Continue reading